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Abstract Hepatitis C virus (HCV)-infected patients often
suffer from liver cirrhosis, which can be complicated by
renal impairment. Therefore, in this review we describe the
treatment possibilities in HCV patients with hepatic and
renal impairment. Cirrhosis alters the structure of the liver,
which affects drug-metabolizing enzymes and drug trans-
porters. These modifications influence the plasma concen-
tration of substrates of drugs metabolized/transported by
these enzymes. The direct-acting antivirals (DAAs) are
substrates of, for example, cytochrome P450 enzymes in
the liver. Most DAAs are not studied in HCV-infected
individuals with decompensated cirrhosis, and therefore
awareness is needed when these patients are treated. Most
DAAs are contraindicated in cirrhotic patients; however,
patients with a Child-Pugh score of B or C can be treated
safely with a normal dose sofosbuvir plus ledipasvir or
daclatasvir, in combination with ribavirin. Patients with
renal impairment (glomerular filtration rate [GFR]
\90 mL/min) or who are dependent on dialysis often tol-
erate ribavirin treatment poorly, even after dose
adjustments. However, most DAAs can be used at the
normal dose because DAAs are not renally excreted. To
date, grazoprevir plus elbasvir is the preferred DAA regi-
men in patients with renal impairment as data are pending
for sofosbuvir patients with GFR \30 mL/min (as for
ledipasvir and velpatasvir). However, sofosbuvir has been
used in a small number of patients with severe renal
impairment and, based on these trials, we recommend
sofosbuvir 400 mg every day when no other DAA regimen
is available. Ledipasvir and velpatasvir are not recom-
mended in patients with severe renal impairment.
Key Points
All drugs used in hepatitis C virus (HCV) treatment
can be used in patient with compensated liver
cirrhosis (Child-Pugh score A).
All drugs used in HCV treatment can be used in
patients with moderate renal insufficiency
(glomerular filtration rate [GFR] C30 mL/min).
In patients with GFR B29 mL/min or advanced liver
disease, HCV drugs might be contraindicated or
dosage adjustments may be necessary.
1 Introduction
Chronic hepatitis C virus (HCV)-related liver cirrhosis is
the leading cause of liver transplantation in many countries
[1–3]. Eventually, 15–30 % of chronically infected HCV
patients develop liver cirrhosis [4, 5]. Symptoms of
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decompensated cirrhosis are portal hypertension (with
increased risk for variceal bleedings), ascites, hepatic
encephalopathy, and hepato-renal syndrome. In addition,
cirrhotic patients have an enhanced risk of hepatocellular
carcinoma, which is an important cause of mortality [6, 7].
HCV is associated with both renal and hepatic impair-
ment, and care must be taken when prescribing direct-
acting antivirals (DAAs) in these patients. The drugs
described in this review are ribavirin and the novel DAAs.
Impaired kidney or liver function may result in altered
drug concentrations, causing either toxicity or subthera-
peutic levels, because these organs are mainly responsible
for metabolizing and excreting drugs. For instance, patients
with reduced renal function have a decreased ability to
eliminate water-soluble agents [8] and patients with
impaired liver function have reduced expression of drug-
metabolizing enzymes and thus reduced metabolizing
capacity [6].
There is only limited information on the pharmacoki-
netics, safety, efficacy, and dosage in these special popu-
lations. Moreover, this information is often difficult to find
and not presented in a comprehensive manner. Therefore,
the aim of this review is to give an overview of the phar-
macokinetics, efficacy, and safety of drugs used for HCV
treatment in patients with renal or hepatic impairment and
to provide dose recommendations for prescribing these
drugs in these special populations.
2 Methods
An extensive search was performed using PubMed (1946 to
October 2015) and EMBASE (1947 to October 2015) to
identify peer-reviewed studies containing information on
pharmacokinetics, efficacy, and safety in patients with
impaired renal or hepatic function and HCV medication.
Search terms used included generic and brand names.
Various general search terms were also used describing
impaired renal and hepatic function, e.g., ‘end stage renal
disease’ (ESRD), ‘dialysis’, ‘cirrhosis’, and ‘hepatic
impairment’. Google, Google Scholar, and ClinicalTri-
als.gov were used to identify conference papers and
abstracts. All searches were performed in the English
language. Additional articles and primary sources were
identified with citation snowballing. Lastly, the summary
of product characteristics (SmPC) approved by the Euro-
pean Medicines Agency (EMA) and the US Food and Drug
Administration (FDA) prescribing information were main
sources of information for this review.
This review focuses on the novel DAAs, e.g., simepre-
vir, paritaprevir, asunaprevir, grazoprevir, daclatasvir,
ombitasvir, ledipasvir, elbasvir, velpatasvir, sofosbuvir,
and dasabuvir. To date, velpatasvir is not yet licensed. The
included DAAs are used in international guidelines [9, 10]
or were submitted for registration up to November 2015 by
the EMA and/or FDA. Ribavirin is also discussed because
it is still a component of the therapy for cirrhotic patients.
We omitted telaprevir and boceprevir from the review as
their current use is limited. Additionally, we do not
describe peginterferon-a as we believe it should not be
used in patients with cirrhosis or renal impairment.
3 Pharmacokinetics
This section summarizes the pharmacokinetics of drugs
used in HCV treatment, in both healthy subjects and in
patients with impaired renal or hepatic function: DAAs
(protease inhibitors [PIs], NS5A inhibitors, NS5B poly-
merase inhibitors, and fixed-dose regimens) and other
antivirals (ribavirin). The clinical consequences and dosage
recommendations based on these observations are sum-
marized in Tables 1 and 2. Figure 1 gives an overview of
the hepatic and renal metabolism of these drugs.
3.1 Protease Inhibitors
3.1.1 Simeprevir
Simeprevir is a second-wave, first-generation PI and is
prescribed at a dose of 150 mg/day. Simeprevir is highly
bound to plasma proteins ([99.9 %), and is a substrate of
various drug transporters such as P-glycoprotein (P-gp),
organic anion-transporting polypeptide (OATP) 1B1,
OATP1B2, OATP2B1, and multidrug resistance protein
(MRP2), and different cytochrome P450 (CYP) enzymes
(intestinal CYP3A4, CYP2C19, and CYP2C8). The plasma
concentration of simeprevir was two- to three-fold higher
in HCV-infected patients than in healthy subjects [11].
Compared with healthy individuals, simeprevir steady-
state area under the plasma concentration–time curve
(AUC) was 2.4- and 5.2-fold higher in Child-Pugh score B
(CP-B) and score C (CP-C) patients, respectively. There-
fore, the manufacturer recommends that simeprevir should
not be used in CP-C patients and that caution should be
taken in CP-B patients [11]. Another trial reported similar
results: non-HCV CP-B patients had twofold increased
exposure compared with healthy individuals and CP-C
patients had twofold higher exposure to simeprevir than
CP-B patients [12]. After a dose of 150 mg, Sekar et al.
[13] observed equal exposure and protein binding between
non-HCV Child-Pugh score A (CP-A) and CP-B subjects.
The steady-state AUC of simeprevir increased (62 %) in
patients with severe renal impairment (Glomerular Filtra-
tion Rate [GFR]: 15–29 mL/min). This may indicate that
exposure may increase in patients with severe renal
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































592 E. J. Smolders et al.
impairment and ESRD (GFR B15 mL/min). Thus caution
is needed in these patients. However, the label states that
simeprevir can be used by patients with all grades of renal
impairment. At last, simeprevir is not removed by dialysis
[11].
3.1.2 Asunaprevir
Asunaprevir is a PI that has activity against multiple
genotypes. It is used at a dose of 100 mg twice daily which
is metabolized by the liver (CYP3A4) and mainly excreted
through the biliary system. Asunaprevir is 98.8 % bound to
serum proteins [14, 15].
The pharmacokinetics of asunaprevir were studied in
non-HCV infected subjects with CP-A/B/C and compared
with healthy volunteers; they were comparable in CP-A
subjects and controls. Maximum concentration (Cmax) and
AUC increased 10- and 5-fold in CP-B subjects and 23-
and 32-fold in CP-C subjects, respectively. Therefore, it is
not recommended that CP-B/C patients be treated with
asunaprevir. Protein binding in all groups was[99.5 % and
the unbound fraction was ± 0.004 [14].
Asunaprevir was studied in non-HCV subjects depen-
dent on dialysis compared with healthy controls. Protein
binding, Cmax, AUC, and trough concentration (Ctrough)
were not affected by dialysis [16]. Comparable results were
presented in an open-label study in HCV-uninfected sub-
jects with normal (GFR [90 mL/min), mild (GFR
50–89 mL/min), moderate (GFR 30–49 mL/min), or sev-
ere renal disease (GFR\30 mL/min) or patients dependent
on dialysis. Subjects received asunaprevir, daclatasvir, and
beclabuvir (NS5B inhibitor). ESRD subjects had slightly
decreased asunaprevir concentrations. Subjects with mod-
erate and severe renal impairment had increased Cmax (65
and 100 %, respectively) and AUC (50 and 76 %, respec-



























Fig. 1 Overview of the hepatic or non-enzymatic metabolism of
drugs used for the treatment of hepatitis C: cytochrome P450 enzymes
involved and biliary and/or renal excretion of drug (metabolites).
Asterisk The site of metabolism is unknown but two metabolizing
pathways are involved: (1) a reversible phosphorylation pathway; and
(2) a degradative pathway involving deribosylation and amide
hydrolysis. Plus or minus Sofosbuvir is extensively metabolized in
the liver in the active metabolite GS-461203, followed by dephos-
phorylation which results in the inactive compound GS-331007. ASV
asunaprevir, CYP cytochrome P450, DCV daclatasvir, DSV dasabuvir,
EBV elbasvir, GRZ grazoprevir, LDV ledipasvir, OBV ombitasvir,
PTV paritaprevir, RBV ribavirin, SIM simeprevir, SOF sofosbuvir,
VPV velpatasvir
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3.2 NS5A Inhibitors
3.2.1 Daclatasvir
Daclatasvir is an NS5A inhibitor that is administered at a
dosage of 60 mg/day. Daclatasvir is highly bound to
plasma proteins (99 %). It is hepatically metabolized
(CYP3A4) and is a substrate of P-gp. Biliary excretion is
the major route of elimination.
Compared with healthy volunteers, Cmax and AUC (total
daclatasvir = unbound and bound drug) values were lower
in non-HCV patients with CP-A/B/C after a single dose of
daclatasvir 30 mg. However, there was no influence on the
unbound fraction of daclatasvir when CP-B/C patients were
compared with HCV-infected controls [18, 19].
Patients with mild, moderate, severe, or end-stage renal
disease had increased unbound daclatasvir AUCs of 18, 39,
51, and 20 %, respectively, compared with normal renal
function. A similar trend was seen in total daclatasvir
exposure. Although the exposure was affected, the authors
concluded that no dose adjustments are necessary in
patients with renal impairment and that these differences
are within the high inter-individual variability of dacla-
tasvir pharmacokinetics [18, 20].
The steady-state pharmacokinetics of daclatasvir 60 mg
have been studied in combination with asunaprevir and
beclabuvir in patients with moderate and severe renal
impairment, showing increased exposure of daclatasvir
(Cmax 35 and 45 %, and AUC 50 and 65 %, respectively).
Patients undergoing dialysis had comparable pharmacoki-
netic parameters with healthy subjects [17].
3.3 NS5B Polymerase Inhibitors
3.3.1 Sofosbuvir
Sofosbuvir is an NS5B polymerase inhibitor that is
administered at 400 mg/day. Sofosbuvir is intracellulair
metabolized and forms the active metabolite GS-461203,
followed by dephosphorylation resulting in the inactive
compound GS-331007. GS-331007 is primarily renally
excreted (78 % of the administered dose). Sofosbuvir is a
substrate of P-gp and breast cancer resistance protein
(BCRP) and is 61–65 % bound to plasma proteins. GS-
331007 is minimally bound to plasma proteins [21, 22].
In a study of the pharmacokinetic properties of sofos-
buvir, the steady-state AUC of sofosbuvir 400 mg fol-
lowing 7-day dosing in CP-B and CP-C patients increased
126 and 143 %, respectively, relative to control subjects.
The GS-331007 AUC was slightly increased: 18 and 9 %
[23]. Lawitz et al. [24] reported increased Cmax and AUC
values of sofosbuvir of 80 and 130 %, respectively, in
patients with hepatic impairment (CP-B and CP-C) com-
pared with non-cirrhotic controls. The pharmacokinetics of
GS-331007 were similar in these three groups.
In patients with mild, moderate, and severe renal
insufficiency sofosbuvir, AUC values were elevated by 61,
107, and 171 % compared with controls. GS-331007 AUC
values was 55, 88, and 451 % higher in these patients.
Administration before and after dialysis influenced the
exposure to GS-331007 as it is removed during dialysis.
After 4 h of dialysis, 18 % of the administered dose had
been removed [23, 25]. A study comparing sofosbuvir
400 mg every day or only on the day of dialysis showed
that there was no accumulation of sofosbuvir or GS-331007
in both treatment groups [26]. Gane et al. treated patients
with severe renal impairment with daily sofosbuvir 200 mg
and low-dose ribavirin. Compared with historical controls
the patients had comparable sofosbuvir exposure and
fourfold higher GS-331007 concentrations [27]. A recently
presented study of ten patients describing the steady-state
pharmacokinetics of sofosbuvir in patients with a GFR of
\30 mL/min (mean creatinine clearance 26.2 mL/min)
showed comparable results. Exposure to GS-331007 and
sofosbuvir increased 6- and 1.4-fold, respectively, com-
pared with patients with normal renal function [28].
The manufacturer does not recommend using sofosbuvir
in patients with severe renal impairment or ESRD, since
studies are still ongoing (NCT01958281 [29]). The main
issue might be the increased exposure to GS-331007 (AUC
451 %). This is caused by decreased clearance of GS-
331007. However, increased exposure of GS-331007 is not
associated with increased toxicity [30].
Several small studies and case reports have shown that
both low-dose (200 mg) and normal-dose (400 mg)
sofosbuvir were overall well-tolerated [26, 31]. Pending
more definite results of ongoing studies, we recommend
patients be treated with sofosbuvir 400 mg/day (GFR
\30 mL/min or ESRD) in case there is no safer DAA
option available. We base this advice on a number of
arguments. First, accumulation of sofosbuvir does not take
place in patients dependent on dialysis, suggesting that a
standard dosage of 400 mg/day will produce similar con-
centrations of active intracellular metabolites independent
of renal function [26]. Secondly, (interim) analyses of
small studies show that sofosbuvir at standard doses is
well-tolerated in these patients groups. Lastly, data are
available for the sustained virologic response (SVR) at
week 12 (SVR12) of patients treated with half-dose
sofosbuvir, which varied from 40 to 90 % [28, 32]. Patients
treated with sofosbuvir 400 mg/day reached SVR12 in
60–100 % of cases [28, 33]. These results suggest that a
reduced dose of the prodrug sofosbuvir may result in lower
concentrations of active intracellular metabolites.
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3.4 Fixed-Dose Regimens
3.4.1 Ledipasvir/Sofosbuvir
Ledipasvir is an NS5A inhibitor available in a fixed-dose
tablet with sofosbuvir containing sofosbuvir 400 mg and
ledipasvir 90 mg. The metabolism of ledipasvir is unknown
but unchanged ledipasvir is mainly found in feces, indicating
biliary excretion. It is a substrate of P-gp and BCRP and it is
[99.8 % bound to plasma proteins [21].
No relevant differences were seen in between the
pharmacokinetics of control patients with normal hepatic
function and CP-C patients after a dose of ledipasvir 60 mg
[21]. Single and multiple doses of ledipasvir 30 mg (in
combination with 200 mg of the investigational PI
vedroprevir) resulted in a reduction of the Cmax (36 %) and
an extended elimination half-life (t) in CP-C patients
(84.4 vs. 45.7 h in healthy subjects). The free fraction of
ledipasvir increased in patients with severe hepatic
impairment (0.21 vs. 0.11 % in healthy subjects). No sig-
nificant changes were seen between CP-B patients and
control subjects [34].
No pharmacokinetic differences were observed between
healthy subjects and patients with severe renal impairment,
although no safety data are available for patients with GFR
\30 mL/min or ESRD (Sect. 4.4.1) [21, 35].
The pharmacokinetics of sofosbuvir in patients with
impaired renal and hepatic function are discussed in Sect.
3.3.1.
3.4.2 Velpatasvir/Sofosbuvir
Velpatasvir is a novel NS5A inhibitor that will probably be
licensed in a fixed-dose tablet with sofosbuvir (100 mg/
400 mg) [36, 37]. Velpatasvir is primarily metabolized by
the liver and excreted through the biliary system. Vel-
patasvir is substrate of P-gp and OATPs, and strong
inducers or inhibitors of CYP influence the plasma con-
centration of velpatasvir, suggesting it is a substrate of
CYP enzymes [38, 39].
Non-HCV subjects with CP-B and CP-C received a
single dose of velpatasvir 100 mg and the AUC from time
zero to infinity (AUC?) was comparable with subjects with
normal hepatic function: AUC? decreased 17 % and
increased 14 %, respectively. However, Cmax in both
groups decreased *50 % and the unbound fraction
increased with decreasing hepatic function [40].
A study in HCV-uninfected subjects with GFR\30 mL/
min showed that renal insufficiency had a modest influence
on the pharmacokinetics of velpatasvir (single dose of
100 mg). Cmax was increased 11 % and AUC? increased
50 % [41]. Further studies are ongoing and the results are
still pending (NCT02185794) [42].
3.4.3 Grazoprevir/Elbasvir
Grazoprevir (PI) and elbasvir (NS5A inhibitor) are newly
licensed in the USA and data from phase III studies were
recently published. Grazoprevir is a substrate of CYP3A4,
P-gp, and OATPs and prescribed in a dosage of
100 mg/day [43]. Exposure to grazoprevir was approxi-
mately one- to two-fold higher in HCV patients than in
healthy controls [44–46].
Elbasvir is prescribed in a dose of 50 mg/day. It is a
substrate of CYP3A4, P-gp, and OATP [47]. Both elbasvir
and grazoprevir are highly hepatically metabolized and less
than 1 % is renally extracted [43, 48].
Jacobson et al. [49] presented pharmacokinetic data of
grazoprevir plus elbasvir in HCV patients with CP-B. CP-B
patients received grazoprevir 50 mg and elbasvir 50 mg
and healthy controls received normal-dose grazoprevir and
elbasvir. Despite the reduced dose, grazoprevir AUC and
Ctrough values were increased 30 and 73 %, respectively,
compared with controls. Elbasvir exposure was comparable
between these two groups [49]. However, the fixed-dose
combination is only available in a dose of grazoprevir
100 mg and elbasvir 50 mg; therefore, and due to a lack of
safety and efficacy data, the combination is contraindicated
for CP-B and CP-C patients [50].
Pharmacokinetic data are available in non-HCV patients
with GFR \30 mL/min and in patients dependent on
dialysis. Dialysis did not influence the steady-state phar-
macokinetics of both grazoprevir and elbasvir. Grazoprevir
was slightly removed by dialysis (\0.5 %) and elbasvir
was not removed. Subjects with GFR\30 mL/min (not on
dialysis) had increased grazoprevir and elbasvir exposure.
AUC and Ctrough values of grazoprevir were elevated 65
and 60 % compared with controls (GFR [80 mL/min).
Elbasvir pharmacokinetics showed similar results: AUC
was 86 % higher and Ctrough was 107 % higher. The
unbound fraction of grazoprevir was comparable between
the three treatment groups. The unbound fraction of
elbasvir was below the limit of detection [32, 50].
3.4.4 Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir
The fixed-dose combination of paritaprevir (75 mg),
ritonavir (50 mg), and ombitasvir (12.5 mg) is adminis-
tered as two tablets once daily with or without dasabuvir
250 mg twice daily.
Paritaprevir is a second-generation PI, which is a sub-
strate of CYP3A4/5, P-gp, OATP1B1, and OATP1B3.
Ritonavir is added to improve the pharmacokinetics of
paritaprevir by inhibiting CYP3A4 (‘boosting’). Pari-
taprevir itself also inhibits various drug transporters and is
97–98.6 % bound to plasma proteins. After hepatic meta-
bolism, paritaprevir is excreted through the biliary system.
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CP-C patients had 3.2- and 9.5-fold higher Cmax and AUC
values than control subjects [51, 52]. Paritaprevir is
contraindicated in CP-B/C patients. The unbound fraction
was 1.1 % in subjects with normal hepatic function and
0.78, 0.75, and 1.2 % by patients with CP-A, CP-B, and
CP-C, respectively.
In patients with mild, moderate, and severe renal
insufficiency, the AUC of paritaprevir increased by 19, 33,
and 45 %. Cmax was comparable with control subjects [51].
Ombitasvir is an NS5A inhibitor and highly metabo-
lized: only 8.9 % of the unchanged drug is excreted, and a
total of 13 metabolites were identified. Amide hydrolysis
and oxidative metabolism are responsible for its biotrans-
formation. Ombitasvir is[99.9 % bound to plasma pro-
teins and biliary excretion is the major elimination
pathway. In CP-C patients, ombitasvir reduced the AUC
and Cmax values by 68 and 54 %, respectively. The
unbound fraction of ombitasvir increased from *0.020 %
in control subjects and CP-A/B patients to 0.047 % in CP-
C patients [51, 52]. Ombitasvir exposure was not affected
by any degree of renal insufficiency [51].
Dasabuvir is an NS5B polymerase inhibitor and a sub-
strate of CYP2C8, CYP3A4, P-gp, BCRP, and organic
cation transporter (OCT) 1. Dasabuvir is hepatically
metabolized into seven metabolites, of which M1 accounts
for 21 % of the administered dose. However, unchanged
dasabuvir accounts for 60 % of the exposure. Dasabuvir is
[99.5 % and M1 94.5 % bound to plasma proteins. The
AUC values of dasabuvir and M1 were equal in healthy
controls and CP-A patients. CP-B patients had reduced
dasabuvir and M1 AUC values (16 and 57 %, respec-
tively). CP-C patients had elevated AUCs for dasabuvir
and M1: 325 and 77 %, respectively [52, 53]. Dasabuvir
unbound fractions were lower in patients with CP-A, CP-B,
and CP-C: 0.29, 0.28, and 0.42 %, respectively (control
subjects: 0.61 %). The unbound fraction of M1 in control
subjects was 5.8 % and it was 5.1, 5.4, and 6.8 % in CP-A,
CP-B, and CP-C patients [52]. Due to the elevated AUC of
dasabuvir (and M1) in CP-C patients, dasabuvir is con-
traindicated in these patients.
The AUC of dasabuvir decreased in patients with mild
(21 %), moderate (37 %), and severe (50 %) renal insuf-
ficiency. As exposure slightly declines in patients with
renal impairment, no dose adjustments are required in these
patients [53].
To conclude, paritaprevir/ritonavir plus ombitasvir with
or without dasabuvir can be used safely in patients with any
stage of renal impairment. Due to a recent FDA
announcement, the label for this combination regimen has
been updated, stating that paritaprevir/ritonavir and ombi-
tasvir with or without dasabuvir is contraindicated for both
CP-B and CP-C patients. These changes have been made
based on results from post-marketing surveillance showing
liver decompensation and liver failure in patients with




Ribavirin is a guanine analog with activity against a range
of RNA and DNA viruses. Ribavirin is always prescribed
as part of a combination therapy. In general practice, rib-
avirin is administered in a weight-based dose
(\75 kg = 1000 mg/day; C75 kg = 1200 mg/day),
although this may differ by genotype and commercial
product [56, 57]. The t of ribavirin is *300 h and
approximately 61 % of the administered dose is renally
excreted, of which 17 % is unchanged ribavirin. The site of
metabolism is unknown but two metabolizing pathways are
involved: (1) a reversible phosphorylation pathway; and (2)
a degradative pathway involving deribosylation and amide
hydrolysis [57]. It is notable that the ratio of whole
blood:plasma is 60:1 and the volume of distribution (Vd) is
5000L, which is caused by the extensive accumulation of
ribavirin in the erythrocytes [56, 57].
The SmPC states that the pharmacokinetics of ribavirin
are similar in control subjects and patients with CP-A/B/C
and therefore no dose adjustments were deemed necessary
in patients with cirrhosis [56]. By contrast, a single-dose
study described an increased Cmax with increasing severity
of cirrhosis (the AUC was not significantly different
between those patient groups) [58].
Patients with moderate or severe renal impairment had
20–30 % higher ribavirin exposure despite adjusted daily
doses of 600 and 400 mg, respectively. ESRD patients had
20 % lower ribavirin plasma exposure when given 200 mg
daily than did subjects with GFR[80 mL/min receiving
the standard dose [56].
Brennan et al. [59] studied steady-state plasma con-
centrations in patients with renal impairment. Data were
hard to interpret because many dose adjustments were
necessary due to toxicity in patients with moderate and
severe renal insufficiency. At week 12 of treatment, these
patients had 36 and 25 % higher AUCs with adjusted daily
doses of 600 and 400 mg, respectively, compared with
control subjects. The apparent total clearance of ribavirin
from plasma (CL/F) was 20.0 L/h in patients with normal
renal function but decreased in patients with renal insuffi-
ciency, ranging from 5 to 6 L/h [59]. In a single-dose
study, increased AUC and decreased clearance were lin-
early correlated with the severity of renal dysfunction
(single dose of 400 mg) [60].
Taking into account the information from the literature
and our clinical experience with ribavirin [61, 62], we
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recommend a weight-based loading dose of ribavirin fol-
lowed by 200 mg/day in patients with severe renal dys-
function or ESRD. We also recommend alternating 200 and
400 mg/day in patients with moderate renal function.
Steady-state plasma concentrations of ribavirin are directly
achieved using a loading dose, which is necessary due to its
long t. Ribavirin is not removed by dialysis and these
patients often have lower hemoglobin levels. Caution is
needed due to accumulation of ribavirin in the erythrocytes
causing hemolysis. If available, therapeutic drug monitor-
ing can be helpful to individualize treatment with ribavirin
in patients with impaired and/or variable renal function.
4 Efficacy and Safety
HCV therapy consists of combinations of drugs, and
therefore efficacy and safety are mostly evaluated in
patients using combination therapy, making data hard to
interpret for only one drug. Efficacy and safety data are
shown in Table 3 for CP-A/B/C patients. Table 4 presents
the data for patients with mild, moderate, severe, and end-
stage renal disease; only multiple-dose studies performed
in HCV patients are included.
4.1 Protease Inhibitors
4.1.1 Simeprevir
Adverse events (AEs) were retrospectively reported in
22 % of CP-A/B HCV genotype 1 patients (n = 119)
treated with simeprevir and sofosbuvir ± ribavirin. SVR
was reached in 78 % of the CP-A/B patients (n = 84), of
whom 29 % were CP-B patients [63]. Another retrospec-
tive study, in which CP-B/C patients were treated with
sofosbuvir and simeprevir, reported that 9 % of patients
discontinued due to AEs (CP-A = 1 % discontinued).
These patients were hospitalized more often than CP-A
patients. Furthermore, 91 % of the CP-A patients reached
SVR versus 73 % of the CP-B/C patients [64]. Both the
EMA and FDA have warned of possible safety issues with
CP-B/C patients because simeprevir safety data are lacking
[11, 65].
In an observational study including ESRD patients with
or without dialysis (n = 17) treated with simeprevir and
sofosbuvir, AEs were reported in 23 %. No patient dis-
continued due to an AE [33]. Trials describing treatment
with a reduced dose of sofosbuvir and simeprevir are dis-
cussed in Sect. 4.3.1 [66, 67].
4.1.2 Asunaprevir
An open-label, randomized, uncontrolled trial with dacla-
tasvir 30 mg, asunaprevir 200 mg, and beclabuvir 75 mg
twice daily reported SVR rates of*94 % in naive cirrhotic
patients. Treatment-experienced patients had SVR rates
C87 %. Ribavirin increased treatment response. Nine
patients experienced a serious AE (SAE) and three patients
discontinued the study due to AEs. The authors concluded
that most AEs were caused by ribavirin and that there were
no significant differences between cirrhotic and non-cir-
rhotic patients [68]. In a trial including genotype 1- and
4-infected cirrhotic patients (METAVIR score F3/4;
n = 223), an SVR of 84 % was reported after treatment
with daclatasvir and asunaprevir. Pooled analyses of four
phase II/III studies showed that SVR was reached in 84 %
of genotype 1b cirrhotic patients (n = 229). No meaningful
differences in safety were described between cirrhotic and
non-cirrhotic patients. Overall, most reported AEs were
headache, fatigue, nausea, and diarrhea (C10 %) [69].
An SVR of 96 % was reached in dialysis-dependent
genotype 1 patients when treated with daclatasvir 60 mg
and asunaprevir 100 mg (n = 21). Of these patients, 97 %
experienced an AE. Anemia (29 %) and nasopharyngitis
(29 %) were the most commonly reported AEs [70].
4.2 NS5A Inhibitors
4.2.1 Daclatasvir
The safety and efficacy of daclatasvir in cirrhotic patients
was studied in combination with asunaprevir (described in
Sect. 4.1.2) or sofosbuvir ± ribavirin. In combination with
sofosbuvir 400 mg, an SVR of 83 % was reached in CP-A/
B/C patients (phase III trial). SVR rates in CP-C patients
were lower: 56 % (compared with CP-A/B patients: 93 %).
In this trial, anemia (20 %), fatigue (18 %), and nausea
(17 %) were the most commonly reported AEs, of which
18 % were grade 3–4 [71]. Another open-label, phase III
study included patients with cirrhosis/advance fibrosis
(genotype 3) who were treated with sofosbuvir 400 mg and
daclatasvir 60 mg (n = 50). These patients most com-
monly reported insomnia (30 %), headache (24 %), and
fatigue (20 %) [72]. No SVR was reported in this prelim-
inary analysis.
Daclatasvir, in combination with asunaprevir and
beclabuvir, was overall well-tolerated by patients with
renal impairment. SAEs were reported in 67 % of the
patients and SVR was C96 % (n = 21) [70].
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4.3 NS5B Polymerase Inhibitors
4.3.1 Sofosbuvir
No SAEs were reported in a multiple-dose study where
400 mg of sofosbuvir was administered to HCV-infected
CP-B/C patients (n = 17) [24]. Sofosbuvir-containing
regimens were in general well-tolerated in patients with
advanced cirrhosis. Fatigue, nausea, headache, and anemia
were the most frequently reported AEs (C10 %) [73, 74].
SVR rates varied from 29 to 91 %, depending on genotype,
Child-Pugh score, and other DAAs (Table 3) [63, 64, 73,
74].
Sofosbuvir was well-tolerated in dialysis-dependent
patients treated with sofosbuvir 200 mg daily or 400 mg
every day or on the day of dialysis [26]. However, as
discussed, the SVR12 of patients treated with half-dose
sofosbuvir varied from 40 to 90 % [28, 32, 66, 67]. Two
other recently presented studies (n = 17 and 10) concluded
that full-dose sofosbuvir (400 mg/day) had good tolera-
bility and was safe in patients with GFR\30 mL/min with
and without dialysis. SVR12 was reached in 60–100 % of
the patients [28, 33]. There was no evidence of an elevated
risk of sofosbuvir-related toxicity. No cardiac toxicity was
reported [28]. A longitudinal, observational cohort reported
SVR rates of 85 % (n = 18), 81 % (n = 63), and 88 %
(n = 168) in patients with severe, moderate, and mild renal




A phase II study with ledipasvir and sofosbuvir ± rib-
avirin reported AEs in 98 % of the CP-B (n = 59) and
100 % of the CP-C (n = 49) patients. Of these patients, 22
and 35 %, respectively, experienced an SAE. SVR was
reached in C82 and C91 % of the CP-B and CP-C patients,
respectively [75]. A randomized, double-blind, placebo-
controlled trial reported[96 % SVR. These patients had a
CP score of 5–7. Asthenia (52 %) and headache (34 %)
were the most common AEs in this trial [76]. Studies in
patients with renal impairment and ledipasvir are still
ongoing (NCT01958281 [29]).
4.4.2 Velpatasvir/Sofosbuvir
A randomized, double-blind, placebo-controlled trial
described the use of velpatasvir in HCV patients with CP-B
in combination with sofosbuvir (genotype 1–6). Different
treatment regimens were used (Table 3) and SVRs C83 %
were reported. Overall, this combination was well-toler-
ated. The most reported AEs were fatigue, nausea, and
headache (C20 %). In total, nine patients discontinued
treatment due to an AE [77]. No studies have been pub-
lished yet describing the safety of velpatasvir in HCV
patients with renal insufficiency.
4.4.3 Grazoprevir/Elbasvir
The safety and efficacy of grazoprevir plus
elbasvir ± ribavirin in CP-A patients was studied in a
phase II trial. SVR was reached in more than 90 % of the
patients (n = 253). More discontinuations due to AEs (2
vs. 0 %) and drug-related AEs (71 vs. 54 %) were seen in
the patients treated with grazoprevir, elbasvir, and rib-
avirin. The regimen was well-tolerated by the patients [78].
Another phase II trial showed that a reduced dose of gra-
zoprevir (50 mg) and normal-dose elbasvir was well-tol-
erated in CP-B patients (n = 30) despite the increased
exposure. Fatigue (30 %) was the most reported AE and
end of treatment (EOT) response was 100 % (n = 25/30)
[49].
As described in Sect. 3.4.3, increased exposure to gra-
zoprevir and elbasvir was reported in patients with a GFR
\30 mL/min without dialysis. A phase III study presented
safety data for grazoprevir 100 mg and elbasvir 50 mg in
patients with GFR B29 mL/min (n = 111). High rates of
AEs were reported (76 %), but these were comparable with
the placebo group (84 %). SAEs and laboratory abnor-
malities were also comparable between groups. Taking
these results in combination with high SVR rates (*95 %),
it was concluded that this regimen is safe and effective for
the use in patients with renal insufficiency [48].
4.4.4 Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir
The fixed-dose combination of paritaprevir/ritonavir,
ombitasvir, and dasabuvir plus ribavirin in CP-A patients
was studied by Poordad et al. [79]. Of these patients, 91%
reported AEs, 6 % of whom had an SAE. Only 2 % of
patients discontinued the study due to AEs. More AEs were
seen during 24-week treatment than during 12-week treat-
ment (phase III trial) and SVR rates were approximately
94 % (n = 380). As discussed in Sect. 3.4.4, the label of this
combination regimen was adjusted due to information that
became available during post-marketing surveillance.
During a phase I trial, this combination was studied in
patients with severe renal insufficiency (n = 20). An
interim analysis shows that EOT response was 100 %
(n = 14/20). All patients completed the trial but experi-
enced AEs such as anemia (40 %), fatigue (30 %), nausea
(25 %), and diarrhea (25 %) [80].
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4.5 Other Antivirals
4.5.1 Ribavirin
In the past, ribavirin was frequently used in combination
with peginterferon-a, but it is now used as part of DAA
regimens. Anemia was frequently reported in trials where
cirrhotic patients were treated with ribavirin, varying from
2 to 40 % dependent on the combination treatment [63, 66,
71, 81, 82].
Patients with severe and moderate renal impairment who
were treated with peginterferon-a-2a and a daily dose of
ribavirin 400 or 600 mg, respectively, frequently needed
dosage reductions (71 and 54 %). Dosage reductions were
required in 22 and 23 % of ESRD patients treated with a
daily dose of ribavirin 200 mg and subjects with normal
renal function, respectively. ESRD patients had a safety
profile comparable with that of subjects with normal renal
function [56, 59].
5 Discussion
5.1 Influence of Hepatic Impairment on Drug
Pharmacokinetics
Liver cirrhosis is the main complication of chronic HCV
infection. Cirrhosis changes the liver architecture into one
with nodules causing reduction in hepatic blood flow, portal
systemic shunting, capiliarization of sinusoids, and loss in
number and function of hepatocytes. The liver is the main
metabolizing organ, and therefore these changes have a pro-
found influence on metabolism and elimination of drugs [6].
Cirrhosis curtails the metabolizing capacity of the liver
due to decreased levels of CYP enzymes. Various CYP
enzymes are affected (e.g., CYP3A4, CY2A6, CYP2C9),
but the susceptibility depends of the type and severity of
the liver disease. For example, CYP1A2 and CYP2C19 are
sensitive to liver disease, whereas CYP2E1 is less sus-
ceptible. These changes in CYP enzymes may cause
increased drug concentrations of enzyme substrates. This
explains the increased exposure of grazoprevir and pari-
taprevir in cirrhotic patients, because these drugs are
metabolized by CYP3A4. Likewise, the increased sofos-
buvir concentration or increased t of ledipasvir might be
related to the reduced capacity of the liver to metabolize
drugs by enzymes other than CYP enzymes, e.g., uridine
diphosphate-glucuronosyltransferase (UGT) conjugation is
affected in cirrhotic livers. In addition, efflux transporters
may be upregulated, while uptake transporters may be
downregulated. These alterations are not yet fully under-
stood [83]. However, they provide an explanation of
increased simeprevir and grazoprevir concentrations,
because OATP uptake transporters may be downregulated,
causing decreased uptake from the circulation into hepa-
tocytes, resulting in increased plasma concentrations.
Reduced hepatic metabolism affects the first-pass effect.
This pre-systemic metabolism is responsible for metabo-
lizing orally administered drugs prior to entering the sys-
temic circulation. Decreased pre-systemic metabolism
results in elevated bioavailability, as seen with paritaprevir
and grazoprevir. In addition, portal shunting affects hepatic
blood flow. Blood bypasses the liver, leading to an
increased systemic drug concentration as a result of
decreased hepatic metabolism.
In cirrhosis, the liver produces less drug-binding pro-
teins (albumin, a1-acid-glycoprotein). Fewer proteins are
available, and thus the unbound fraction of drugs may be
elevated. Only this unbound fraction of drugs is available
for uptake in the tissues and therefore is responsible for the
pharmacological effect of a drug. The increased unbound
fraction might even cause toxicity despite the total expo-
sure being decreased. This was seen in ombitasvir: the
unbound fraction increased twofold in patients with severe
hepatic impairment but the total AUC was decreased [52].
On the other hand, the AUC of total daclatasvir was
decreased, but the unbound fraction of daclatasvir
remained unchanged in patients with cirrhosis due to
increased clearance of free daclatasvir. This means that no
differences were found in the active concentration of
daclatasvir and therefore there was no need for dose
modifications [19].
Finally, the ribavirin Cmax was increased in patient with
cirrhosis compared with controls. Ribavirin is renally
cleared and extensively metabolized (site unknown). These
changes in Cmax may be caused by alterations in, for
example, hepatic drug transporter activity; however, these
findings could also be caused by the higher inter-individual
variability of ribavirin. Since other pharmacokinetic
parameters were not affected, no dose adjustments are
necessary when using ribavirin in cirrhotic patients.
Figure 2 summarizes the physiological alterations dur-
ing cirrhosis that influence drug concentrations and Table 1
shows the recommended doses or contraindications for CP-
A/B/C patients.
5.2 Influence of Renal Impairment on Drug
Pharmacokinetics
The prevalence of HCV in dialysis patients in Europe and
the USA varies from 3 to 20 %. In 2002, 8 % of the dia-
lyzed patients in the USA were infected with HCV [84].
HCV is both a cause and a consequence of renal impair-
ment: first, patients on dialysis have an increased infection
risk due to medical procedures and, secondly, HCV causes
pathological changes to the kidneys [84, 85].
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Renal dysfunction influences the renal clearance of
drugs. Glomerular filtration, tubular secretion, and tubular
reabsorption are responsible for renal clearance of drugs.
The clearance may be altered due to damage to glomeruli
or by altered activity of drug transporters in tubular cells.
In general, renal impairment results in increased drug
concentrations of renally cleared drugs.
Patients with ESRD are often dependent on dialysis. An
important factor that affects the clearance of drugs is the
molecular weight of the drug in relation to the pore size.
Other parameters influencing drug clearance during
hemodialysis are protein binding, Vd, water solubility, and
plasma clearance. Characteristics of the dialyzer are also
important for the pharmacokinetics of drugs, e.g., the flow
of the blood and dialysate, and the concentration gradient.
As described in Sect. 3, most HCV drugs are highly bound
to plasma proteins, which explains why these drugs are not
removed by dialysis (Table 4) as only unbound drugs can
be removed by dialysis. Additionally, most drugs are
metabolized by the liver, and therefore the contribution of
hemodialysis to the clearance of drugs is relatively low
[86].
In general, DAAs are hepatically cleared, meaning no
dose modifications are necessary in patients with renal
impairment. However, sofosbuvir and ribavirin, which are
primary renally eliminated, are exceptions to this.
Exposure to GS-331007 increased with a decreasing
GFR, but—as explained earlier—dose modification may
not always be advisable. Sofosbuvir is removed during
dialysis and thus it is recommended that it is administered
after dialysis [23].
Ribavirin is mainly situated in the erythrocyte and not
effectively cleared from the body during hemodialysis [59].
This causes increased plasma concentrations, which are
related to (severe) anemia. However, while higher ribavirin
plasma concentrations are related to anemia, they are also
associated with improved SVR. Plasma concentrations of
ribavirin can explain toxicity or give information regarding
whether the ribavirin exposure is sufficient. In other words:
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Fig. 2 Overview of the pathophysiological changes in patients with liver cirrhosis that influence drug metabolism and therefore the
pharmacokinetics of drugs. CYP cytochrome P450, UGT uridine diphosphate-glucuronosyltransferase, ; indicates decrease, : indicates increase
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to toxicity, dose modifications are needed in ribavirin-
treated patients who have a GFR B50 mL/min and in
ESRD patients.
A second consideration is that non-renal clearance is
affected in patients with renal disease. It should be noted
that this phenomenon is mostly studied in patients with
ESRD. CYP enzymes, UGT enzymes, and drug trans-
porters have altered activity in patients with renal insuffi-
ciency, but protein-binding may also decrease. One
hypothesis is that the uremic toxins cause these alterations
in drug transporters and enzymes; dialysis then removes
these toxins, which improves CYP3A- and transporter-re-
lated clearance [90]. These alterations in hepatic function
may affect hepatically cleared drugs such as daclatasvir,
grazoprevir, and elbasvir. Daclatasvir exposure (bound and
unbound) was elevated in patients with decreasing renal
function [20]. Similarly, grazoprevir and elbasvir exposure
increased significantly in patients with a GFR\30 mL/min
[32, 50].
In conclusion, it is hard to predict what the influence of
renal function on the exposure of drugs is. This should be
taken into account when interpreting the dose recommen-
dations in Table 4.
5.3 Studies in Patients with Renal and Hepatic
Impairment During Clinical Development
The effect of renal or hepatic impairment on the pharma-
cokinetics of HCV drugs is often studied in single-dose
studies in HCV-negative patients with renal insufficiency
or liver cirrhosis. These studies give an idea of the phar-
macokinetics in these patients groups, but the influence of
HCV is missing. The virus itself may also influence drug
metabolism, as inflammation and infection are known to
affect CYP activity in the liver [91, 92].
Therefore, studies in HCV-infected patients with
renal or hepatic impairment are performed after licens-
ing and post-marketing surveillance takes place (e.g.,
collecting AEs). These findings might then be used to
change the prescribing information. For example, the
labels of both simeprevir and paritaprevir/ritonavir plus
ombitasvir with or without dasabuvir were recently
changed due to information that became available after
licensing. In our opinion, these studies should be part of
the pre-registration process, since HCV patients suffer
from these conditions and therefore they will be treated
with the novel DAAs. In comparison, sofosbuvir is
contraindicated for patients with a GFR \30 mL/min
because no safety studies have been performed and data
are missing. This might exclude patients unnecessarily
from treatment.
6 Conclusion
This review described the pharmacokinetics, efficacy, and
safety of HCV drugs in patients with renal and hepatic dys-
function. All of the available drugs for the treatment of HCV
can be used in patients with CP-A and in those with a GFR
C30 mL/min. Some drugs are contraindicated in patients
with advanced liver disease (CP-B or CP-C), and sofosbuvir
plus ledipasvir or daclatasvir are the best options for this
group. Patients with a GFR\30 mL/min can be treated with
grazoprevir plus elbasvir or paritaprevir/ritonavir and
ombitasvir with or without dasabuvir. Sofosbuvir is an
important part of HCV therapy, and therefore data on its use
in renally impaired patients is essential information; how-
ever, data on sofosbuvir are still pending. Lastly, it would be
helpful if more pharmacokinetics, efficacy, and safety data
became available for the treatment of patients with advance
liver disease or severe renal impairment. These patients
might benefit the most from therapy, possibly preventing the
need for liver transplantation.
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